Previous Page
12
nanotimes
Companies Facts
the same period in 2010. Net loss under U.S. GAAP for the nine months ended September 30, 2011 was $(7.9) million or $(0.26) per basic and diluted share, compared to net loss of $(13.8) million or $(0.44) per basic and diluted for the nine months ended Septem- ber 30, 2010. Further highlights include:
• Signed multi-year agreements with Eli Lilly and Company and the National Institutes of Health (NIH) / National Institute of Neurological Disor- ders and Stroke (NINDS) to provide drug discovery services;
• 17% growth in Large-Scale Manufacturing; • 8% growth in Development/Small-Scale Manufacturing;
• AMRI to cease all activities related to its internal R&D programs, excluding its generic program, saving approximately $7 million in operating expenses in 2012; Company will immediately wind down programs to focus efforts only on partnering/out-licensing opportunities.
Moreover, AMRI has entered into an agreement with Revolymer®
(U.K.) to become its primary ma-
nufacturer and supplier of Rev7™, AGC and other polymers, main components of the company’s revo- lutionary Rev7™ degradable gum products.
ended September 30, 2011. Revenues for the second quarter of fiscal 2011 were $20.8 million. This com- pares with $98.1 million for the second quarter of fiscal 2010 and $9.1 million for the first quarter of
A
MSC (NASDAQ: AMSC) reported financial results for its second quarter of fiscal year 2011
from Roche (SIX: RO, ROG; OTCQX: RHHBY) in- cluding the state-of-the-art research site in Madison, WI, USA. “This acquisition is transformational for us and im- portant to the broader RNAi field,” said Dr. Christo-
A
rrowhead Research Corporation (NASDAQ: ARWR), has acquired RNA therapeutics assets
fiscal 2011. The year-over-year decline is due prima- rily to a lack of revenue from AMSC’s former custo- mer, Sinovel Wind Group Co., Ltd. (Sinovel), while the quarter-over-quarter increase was driven by solid growth in both of the company’s reporting segments (Wind and Grid).
AMSC reported a net loss for the quarter of $51.7 million, or $1.02 per share. Cash, cash equivalents, marketable securities and restricted cash at Sep- tember 30, 2011 were $108.3 million. This com- pares with $166.2 million as of June 30, 2011. The company’s total backlog as of September 30, 2011, excluding contracts related to Sinovel, was approxi- mately $298 million, which compares with approx. $225 million as of June 30, 2011.
shares as the first stage of a placement referred to in the Company’s announcement on October 19, 2011. The total issued capital of Antaria following the allot- ment is 508,839,150 ordinary shares.
ntaria Limited (ASX: ANO) has completed the allotment and issue of 38,500,000 ordinary
11-10 :: October 2011